Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
ABSTRACT Background: Bone marrow angiogenesis is increased in multiple myeloma (MM) patients, prompting the rationale for using antiangiogenic drugs in the treatment of these patients. Objective: To assess angiogenesis in patients with MM at diagnosis and following treatment with an antiangiogenic drug. Patients and Methods: Twenty-three patients with newly diagnosed MM were treated with thalidomide-based regimens. Bone marrow evaluation was made before and following treatment and included angiogenesis assessment, which was quantified through microvessel density (MVD) determination, by means of anti-CD34 immunohistochemical labeling, and classified either as high MVD or low MVD, according to the mean CD34 count: above or below the median of 12.6. Results: The pre-therapy median MVD was 12 (7.5-18.3) versus 8.7 (5.35-18.5) post-therapy, p = 0.2114. Conclusions: Our study found no reduction in MVD before and following treatment and, accordingly, we could establish no relationship between MVD and response to therapy in the sample we studied.
Auteurs principaux: | Cury,Priscilla Cury de Camargo, Higashi,Fabiana, Zacchi,Flávia Fernandes Silva, Palhares,Renata Bacic, Quero,Adriana Alvares, Dias,Ana Luiza Miranda Silva, Crusoé,Edvan de Queiroz, Hungria,Vania Tietsche de Moraes |
---|---|
Format: | Digital revista |
Langue: | English |
Publié: |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
2020
|
Accès en ligne: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792020000200159 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Multiple myeloma and central nervous system involvement: experience of a Brazilian center
par: Dias,Ana Luiza Miranda Silva, et autres
Publié: (2018) -
Outcomes of autologous transplantation for multiple myeloma according to different induction regimens
par: Crusoe,Edvan de Queiroz, et autres
Publié: (2014) -
Bone marrow stem cells and their role in angiogenesis
par: Reis,Paulo Eduardo Ocke
Publié: (2005) -
Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?
par: Crusoe,Edvan de Queiroz, et autres
Publié: (2016) -
Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
par: Crusoe,Edvan De Queiroz, et autres
Publié: (2020)